COVID-19 & Psoriasis Resource Center

To assist dermatologists and the patients they serve, the IPC is collecting information from around the world on coronavirus and psoriasis. If you have a resource on COVID-19 and psoriasis to add, please submit it to IPC.

Latest news on COVID-19 & Psoriasis

Commentary: Vaccine Hesitancy and Access to Psoriasis Care in the COVID-19 Pandemic

May 11, 2022

Focus on Psoriasis: A Report from the 2022 American Academy of Dermatology (AAD) Annual Meeting

April 14, 2022

PsoProtect Registry Data Update

April 13, 2022

Commentary: Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study

January 25, 2022

IPC Statements on COVID-19 & PsoriasisRead statements from IPC’s Board of Directors based on the current understanding of the impact of COVID-19 and psoriasis.

Commentaries

Psoriasis experts from around the world give their take on the most current COVID-19 publications.

Stories from the Field View videos and read interviews from some of IPC's experts regarding the impact on psoriasis care during the COVID-19 pandemic.

Treatment GuidelinesView recommendations from professional and patient societies around the globe that have provided additional information regarding treating patients with psoriasis during the COVID-19 pandemic.

Key Publications Review articles on COVID-19 selected by IPC's Chief Medical Officer.

IPC STATEMENT
on SARS-CoV-2 Vaccines and Psoriasis

Six key take-aways that physicians and other healthcare practitioners should consider when administering the SARS-CoV-2 vaccine to psoriasis patients.

READ FULL STATEMENT

The National Psoriasis Foundation
COVID-19 Task Force Guidance Statements

Twenty-five key recommendations for the management of patients with psoriatic disease during the COVID-19 pandemic.

READ STATEMENTS

THIS WEEKS' PUBLICATIONS ON COVID-19 & PSORIASIS

Nail psoriasis: a rare mRNA COVID-19 vaccine reaction
No abstract

New onset of psoriasis following COVID-19 vaccination
The cutaneous side effects of COVID-19 vaccines are being studied and their immunogenicity is most likely linked to the pathophysiology of psoriasis. Although uncommon, several cases of exacerbation and new onset of psoriasis have been reported globally after vaccination. To contribute to the literature on this intriguing topic, we present three cases of de novo psoriasis in adult patients following COVID-19 vaccination. Our observations and a literature review show that this occurrence is...

Treatment of Moderate to Severe Psoriasis during the COVID-19 Pandemic: Lessons Learned and Opportunities
Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, clinicians have been overwhelmed by questions beyond the SARS-CoV-2 infection itself. In dermatology practice, clinicians have been facing difficulties concerning therapeutic management of chronic immune-mediated skin disease, above all psoriasis. Major challenges arisen were to understand the role of immunosuppression or immunomodulation on COVID-19 evolution, the benefit/risk ratio related to discontinuation or...

Flare-up of generalized pustular psoriasis following Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine: Two cases without mutations of IL36RN and CARD14 genes
No abstract

Risk of hepatitis B reactivation: From biologic therapies for psoriasis to immunosuppressive therapies for COVID-19 (Review)
The cytokine storm from the evolution of severe cases of COVID-19, requiring strong immunosuppressive therapies, has raised the issue of reactivation of hepatitis B virus (HBV) infections in these patients. An analysis of the first observational studies in patients with COVID-19 and immunosuppressive therapy and HBV infection along with special clinical cases was presented, as well as personal experience on a series of cases (a group of 958 patients with COVID-19), compared with the analysis of...

VIEW ALL ON PUBMED

RECOURCES FROM OUR INDUSTRY PARTNERS

AbbVie
Amgen
Novartis
UCB